Abstract
Considerable evidence have established the importance of specific nutrients that have been found vital for the developing brain. We hypothesize that in a similar manner there should be nutrients vital to the aging brain and that based on its distinct pathophysiology they should be different than those essential to development. Specific brain networks that govern cognition are particularly vulnerable to the aging process, resulting in what is referred to as ‘cognitive aging’. Common late-life disorders, however, such as Alzheimer’s disease also target these same brain networks. Studies have disambiguated cognitive aging from late-life disease by isolating regions and biological pathways within each network differentially linked to one or the other. This anatomical biology anchors a framework to identify nutrients relevant to cognitive aging whose utility is illustrated via a decades-long research program into how dietary flavanols benefit the brain. As we are living longer in cognitively more demanding lives, the framework’s ultimate goal is to generate specific dietary recommendations that will fortify our mind for its golden years.
Introduction
The identification and validation of folate as a nutrient for the nervous system’s development is considered a crowning achievement of nutritional neuroscience. The search for developmentally-sensitive nutrients began after mid-20th century studies suggested that, in contrast to other developmental malformations, neural tube defects are linked more closely to environmental rather than genetic factors1. While folate was first implicated by observational studies, its etiological role was ultimately validated by rigorous experimental studies using folate biomarkers and by clarifying its precise mechanisms of action.
Might there exist nutrients similarly important for the aging brain? In considering this question, it is notable that modern nutritional science began at a time when the average life expectancy was approximately 50 years. The early focus on nutrients for nervous system development and not aging is therefore understandable. But as life expectancy dramatically climbed during the 20th century there emerged a more important barrier in addressing this question: the biological ambiguity between brain dysfunction caused by the aging process versus that caused by diseases of late life, in particular Alzheimer’s disease2.
Distinguishing Alzheimer’s disease and other neurodegenerative disorders that are typically genetically based3,4 from age-related brain dysfunction is critical because the latter is likely linked more closely to environmental rather than genetic factors. Additionally, in contrast to neurodegeneration, age-related brain dysfunction is less pernicious, mediated by dysfunction of neuronal synapses, never resulting in wholesale neuronal death5. Synaptic function is in principle more likely to be sensitive to subtle environmental factors such as dietary elements and that unlike neuronal death, synaptic dysfunction can be reversed. These pathophysiological distinctions justify the hypothesis that nutrients are mechanistically more likely to be linked to age-related brain dysfunction, and if identified can help to prevent or even in reverse it.
While age-related brain dysfunction and late-life disorders like Alzheimer’s disease target the same cognitive networks of the brain, as reviewed below, studies have disambiguated one from the other by isolating brain regions and underlying biological pathways differentially linked to each. Accordingly, we propose a framework guided by this anatomical biology to identify and validate nutrients that may be etiologically linked to age-related brain dysfunction. This framework is illustrated by a decades-long research program examining how dietary flavanols benefit the brain, highlighting which future studies are needed to validate nutrients that may be vital for the aging brain.
The anatomical biology of brain aging
Among the many brain networks that govern cognition, two are primarily affected by the deleterious effect of the aging process independent of disease, giving rise to what is referred to as ‘cognitive aging’ 6: The prefrontal cortex and its role in executive and related abilities, and the hippocampus, governing the ability to learn and remember new information. The two components of cognitive aging, therefore, are age-related prefrontal dysfunction and age-related hippocampal dysfunction.
The problem is that both brain areas also are affected by neurodegenerative disorders, in particular the most common disorder of late-life, Alzheimer’s disease7. The logic of anatomical biology has been used to distinguish cognitive aging from Alzheimer’s disease. Both areas are networks that comprise different but interconnected brain regions. Each houses neuronal populations that are distinct in their molecular and physiological properties. Since aging and disease are assumed to be mechanistically distinct, anatomical biology predicts that aging and disease should differentially target individual regions within each network driven by distinct biological pathways2.
Over the course of the recent decades, this assumption has been confirmed, particularly for age-related hippocampal dysfunction and to a lesser degree for age-related prefrontal dysfunction. From a series of observational studies in older adults with and without Alzheimer’s disease, aging non-human primates and rodents, mouse models of Alzheimer’s disease (reviewed in8 and more recently9), and interventional studies in older adults without disease10,11, a double-anatomical dissociation has been established within the hippocampal network between aging and Alzheimer’s disease. Across the regions of this network, the dentate gyrus is the hippocampal region identified as differentially vulnerable to aging and a neighboring hippocampal region, the entorhinal cortex, is found differentially resistant to aging (Fig. 1). The reverse pattern is found for Alzheimer’s disease. These anatomical profiles have been used to identify biological pathways whose disruption underlies dentate gyrus dysfunction and drives hippocampal-dependent memory loss in aging12,13, and pathways that when disrupted underlie entorhinal cortex dysfunction in Alzheimer’s disease14,15. Confirming the principle of anatomical biology16, the two pathways are distinct and non-overlapping.
Figure 1. Anatomical biology distinguishes cognitive aging from Alzheimer’s disease.
Both cognitive aging and Alzheimer’s disease target the prefrontal cortex and the hippocampus. As shown in red and biding by the tenets of anatomical biology, compared to disease, cognitive aging differentially targets the inferior frontal gyrus within the prefrontal cortex, and the dentate gyrus within the hippocampus. The entorhinal cortex shown in blue, is the brain’s cortical region most resistant to aging without Alzheimer’s disease, but most vulnerable to Alzheimer’s disease (Adapted from Zeng et al, PLOS One, 2020).
In the case of age-related prefrontal dysfunction, a less extensive series of observational9,17 and interventional studies18 in healthy older adults without disease has identified the inferior frontal gyrus as the region that is differentially targeted by age-related prefrontal dysfunction (Fig. 1), although the underlying biological pathway that drives this dysfunction remains unknown.
Collectively, the anatomical biology of cognitive aging establishes anchoring points in constructing a framework for determining whether there are nutrients that are linked to age-related hippocampal dysfunction on the one hand or age-related prefrontal dysfunction on the other.
Identifying candidate nutrients for the aging brain
The framework proposes that any dietary element linked to the dentate gyrus might be a candidate as a nutrient needed to preserve hippocampal function during aging.
On the heels of a cell culture screen of ‘generally recognized as safe’ compounds that suggested that (–)-epicatechin might be linked to dentate gyrus neurons, mouse studies19 investigated the in vivo effect of (–)-epicatechin, a key component of dietary flavanols commonly found in tea, apples, berries, grapes, cocoa and other fruits and vegetables. These studies showed that (–)-epicatechin improves hippocampal-dependent memory by enhancing angiogenesis and synaptogenesis specifically in the dentate gyrus, and other preliminary studies suggest that it plays a role in improving the biological pathway in the dentate gyrus specifically linked to cognitive aging20.
Inspired by these observations, (–)-epicatechin-enriched dietary flavanols were tested in two randomized-controlled studies to determine whether they target the dentate gyrus to improve hippocampal function in healthy older adults. The first was a relatively small study10 that was designed to mechanistically confirm observational studies implicating the dentate gyrus as the anatomical hub of age-related hippocampal dysfunction. The second study11 included a greater number of participants, tested different levels of (–)-epicatechin-enriched dietary flavanols, collected more information about baseline diet, and had a washout period that tested cognition after the flavanol interventions were stopped.
Results from these studies support the possibility that (–)-epicatechin may act as a nutrient linked to age-related hippocampal dysfunction. Consistent with the framework’s anatomical biology, the (–)-epicatechin-enriched interventions were found to selectively improve hippocampal-dependent memory. Moreover, as suggested by neuroimaging findings, the interventions’ improvement of hippocampal-dependent memory was mediated primarily via the dentate gyrus acting as the hub of the hippocampal network (Fig. 2A).
Figure 2. Anatomical biology generates mechanistic hypotheses.
A. Left panel: MRI Maps of hippocampal cerebral blood volume (CBV), sensitive to capillary density and/or synaptic function, shows that age-related decline localizes primarily to the dentate gyrus (CBV decreases color-coded in red). Right panel: An (–)-epicatechin-enriched dietary intervention in older people results in the greatest increase in CBV localized mainly to the dentate gyrus (CBV increases color-coded in yellow) (From Brickman et al, Nature Neuroscience, 2014).
B. Two growth factors, BDNF and VEGF, have been linked to (–)-epicatechin and to maintaining synaptic and epithelial health. Across cortical and hippocampal regions BDNF, VEGF, and the VEGF receptor (VEGFR) are localized primarily to the dentate gyrus (from the Human Allen Brain Atlas).
More mechanistic support came from the larger study. By assessing baseline habitual diet using the ‘alternative healthy eating’ index (aHEI), a healthy diet selectively correlated with hippocampal-dependent memory and the flavanol interventions improved cognition most reliably in those participants whose study entry dietary quality was poor. Because the aHEI assesses habitual consumption of foods enriched in (–)-epicatechin, these observations provided the first clue that a relative (–)-epicatechin ‘deficiency’ might drive age-related hippocampal dysfunction in older adults.
The washout period also was informative. During the active phase of the study, the participants were randomly assigned to different levels of flavanol consumption or placebo for a 3-month period, at which point the intervention was stopped and the participants were cognitively evaluated after the 8-week washout After this washout phase, the memory improvements of the participants observed at the end of the intervention returned to their study-entry baseline. This ‘ABA’ experimental design strengthens the mechanistic link between (–)-epicatechin enriched dietary flavanols and hippocampal-dependent memory.
Finally, the second study used a newly validated biomarker that measures the main (–)-epicatechin metabolite produced by the gut microbiome and taken up by the body when consumed in dietary flavanols21,22. The biomarker documented a ‘dose’ dependent increase of the (–)-epicatechin metabolite across the flavanol intervention conditions, and a reduction to baseline levels after the washout period. More importantly, levels of the biomarker selectively correlated with hippocampal-dependent not prefrontal-dependent cognitive abilities, providing the first evidence linking (–)-epicatechin per se to hippocampal function in people.
Collectively, this series of translational mouse-to-human studies justifies the conclusion that (–)-epicatechin represents a candidate nutrient for the aging brain.
Validating nutrients for the aging brain
The recent development of the (–)-epicatechin biomarker is a major technical milestone for the goal of validating whether dietary flavanols can be considered the first bona fide nutrient for the aging brain. Just as for folate, the goal standard, a reliable measure of any potential nutrient is required to first show that it is correlated with a disorder’s defining readout, as already documented between the (–)-epicatechin biomarker and dentate gyrus-mediated hippocampal function11.
Just as with folate, but more importantly for validation, it is now possible to incorporate this biomarker into flavanol intervention studies. In this way, the causal logic of ‘depletion-repletion’ can be tested by showing that (–)-epicatechin is not simply a nootropic supplement that benefits all takers, but rather, only benefits those older adults with relatively lower baseline levels of (–)-epicatechin consumption. These two interlinked validating assumptions are currently being tested in the context of a third randomized-controlled study (COSMOS-Web, NCT04582617), this time in thousands of older adults assigned either to an (–)-epicatechin-enriched flavanol intervention vs. placebo control, using the (–)-epicatechin biomarker in conjunction with the ‘alternative healthy eating index’.
A parallel but no less important validation step would be mechanistically explaining precisely why (–)-epicatechin is associated with hippocampal function. Here, too, anatomical biology can guide the generation of specific and testable hypotheses. The dentate gyrus is a brain region particularly sensitive to numerous endogenous blood-born factors23–26 whose levels change during the aging process that, as shown in mice, are associated with age-related hippocampal dysfunction. This differential sensitivity must be explained by cellular and molecular distinctions, which are at least in part explained by the fact that the dentate gyrus is one of the rare brain regions that supports neurogenesis after birth27,28. This unique developmental feature has been hypothesized to ‘imprint’ upon the cells of the dentate gyrus a distinct molecular expression profile8.
(–)-Epicatechin can be considered an exogenous blood-born component of our diets that, as reviewed above, differentially targets the dentate gyrus by inducing regionally-selective angiogenesis and synaptogenesis. Since loss of both capillaries and synapses in the dentate gyrus is precisely what characterizes the cellular pathophysiology of age-related hippocampal dysfunction (Fig. 2A), (–)-epicatechin’s memory-enhancing effect in older adults makes physiological sense. Similar to how an age-related decline in endogenous blood-born factors can specifically target the dentate gyrus, it is now possible to use the (–)-epicatechin biomarker to test whether this exogenous blood-born dietary element declines with age.
What are the molecular mechanisms that link (–)-epicatechin to endothelial and synaptic health in the dentate gyrus? The answer remains unknown and should be considered one cell-type at a time. Since (–)-epicatechin crosses the blood brain barrier, it may directly affect both the endothelium and synapses of the dentate gyrus, perhaps in a synergistic manner.
Starting with endothelial cells, studies have linked (–)-epicatechin to VEGF (Vascular Endothelium Growth Factor) and its secretion29,30, which in this context can be considered a regulator of endothelial health. In fact, in vivo mouse studies have shown that repleting the age-related decline in one of the endogenous blood-born factors rescues age-related dentate gyrus capillary loss by inducing angiogenesis25. This restorative and normalization benefit is associated with increased VEGF secretion from endothelial cells. Across cortical and hippocampal regions VEGF and its receptor appear to be preferentially expressed in the dentate gyrus (Fig. 2), providing a plausible hypothesis for why (–)-epicatechin is mechanistically linked to maintaining endothelial health in the aging dentate gyrus.
Moving to neurons, here another growth factor, BDNF (Brain-Derived Neurotrophic Factor) a known regulator or synaptic health, almost certainly plays a mechanistic role since mouse studies have linked (–)-epicatechin consumption to increased hippocampal BDNF expression31. Even more so than VEGF, BDNF is differentially expressed in the human dentate gyrus (Fig. 2), and so collectively the inescapable hypothesis is that BDNF mediates the link between (–)-epicatechin and synaptic health in the aging dentate gyrus. A second and potentially related hypothesis for how (–)-epicatechin contributes to dentate gyrus synaptic health emerges from the human and mouse studies that have identified a specific histone acetylation pathway that when disrupted is a a causal driver of age-related dentate gyrus dysfunction12,13.
The hippocampus is highly homologous in mice and humans and dentate gyrus-dependent age-related hippocampal dysfunction is phenocopied in both species. Nevertheless, while more easily tested in mice, it is always better to test mechanistic hypotheses about a human condition in humans. In this regard, genetics can be used to test at least the two hypotheses about the mechanistic links between (–)-epicatechin and synaptic health in humans. BDNF loss-function polymorphisms have been identified that are linked to hippocampal-dependent memory32, and variants in genes encoding key proteins of specific histone acetylation pathway have been identified and are linked to age-related hippocampal dysfunction13. Future studies can test whether the cognitive response to (–)-epicatechin interventions will be influenced by those people who carry these genetic polymorphisms and/or variants.
Finally, another mechanistic question worth pursuing is why some people have relatively lower (–)-epicatechin levels. This might simply reflect relatively poorer (–)-epicatechin-enriched diets. Given the fact, however, that even when consumed via a healthy diet, (–)-epicatechin needs to be first metabolized in the gut microbiome before its uptake21, lower (–)-epicatechin levels might reflect the established age-related changes to our microbiome33. If these changes play any role in relative (–)-epicatechin deficiency, even if it somehow interacts with diet quality as would be predicted, future microbiome studies then could isolate the specific gut microbiota that regulate (–)-epicatechin metabolism.
Summary
The framework’s utility for identifying nutrients that are mechanistically linked to cognitive aging was exemplified in the context of dietary flavanols for age-related hippocampal dysfunction. Future studies can rely on this framework to identify other elements in our diets that may fulfill criteria as nutrients for cognitive aging, by targeting either age-related hippocampal or prefrontal dysfunction.
The pathophysiology of cognitive aging supports the hypothesis that, more so than late-life disorders, nutrients not only can drive cognitive aging but that even when initiated nutrients are more likely to ameliorate the process once it has begun. Thus, in contrast to late-life disorders like Alzheimer’s disease, which are more likely to require pharmaceutical interventions, dietary interventions for cognitive aging have the additional bioethical advantage of being more easily accessible to all16.
Just as there currently exist public health recommendations for dietary interventions to fortify the developing nervous system, the ultimate goal of this research enterprise is to begin assembling the equivalent recommendations to fortify our aging minds so that increases in longer, healthier lives are accompanied by preservation in our cognitive abilities.
Acknowledgements:
NIH/NIH (P30AG066462, R01AG058417) Mars Inc., The Simons Foundationt he Nathaniel Wharton Fund.
References
- 1.Oakley GP Jr. The scientific basis for eliminating folic acid-preventable spina bifida: a modern miracle from epidemiology. Ann Epidemiol 19, 226–230, doi: 10.1016/j.annepidem.2009.01.016 (2009). [DOI] [PubMed] [Google Scholar]
- 2.Small SA Age-related memory decline; current concepts and future directions. Archives of Neurology 58, 360–364 (2001). [DOI] [PubMed] [Google Scholar]
- 3.Guerreiro R & Hardy J Genetics of Alzheimer’s disease. Neurotherapeutics 11, 732–737, doi: 10.1007/s13311-014-0295-9 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hardy J, Cai H, Cookson MR, Gwinn-Hardy K & Singleton A Genetics of Parkinson’s disease and parkinsonism. Ann Neurol 60, 389–398 (2006). [DOI] [PubMed] [Google Scholar]
- 5.Morrison JH & Hof PR Life and death of neurons in the aging brain. Science 278, 412–419 (1997). [DOI] [PubMed] [Google Scholar]
- 6.Salthouse TA Selective review of cognitive aging. J Int Neuropsychol Soc 16, 754–760, doi: 10.1017/S1355617710000706 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Braak H & Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239–259 (1991). [DOI] [PubMed] [Google Scholar]
- 8.Small SA, Schobel SA, Buxton RB, Witter MP & Barnes CA A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci 12, 585–601, doi:nrn3085 [pii] 10.1038/nrn3085 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Feng X et al. Brain regions vulnerable and resistant to aging without Alzheimer’s disease. PLoS One 15, e0234255, doi: 10.1371/journal.pone.0234255 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Brickman AM et al. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Nat Neurosci 17, 1798–1803, doi: 10.1038/nn.3850 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sloan RP et al. Insights into the role of diet and dietary flavanols in cognitive aging: results of a randomized controlled trial. Sci Rep 11, 3837, doi: 10.1038/s41598-021-83370-2 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Pavlopoulos E et al. Molecular mechanism for age-related memory loss: the histone-binding protein RbAp48. Sci Transl Med 5, 200ra115, doi: 10.1126/scitranslmed.3006373 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Barral S, Reitz C, Small SA & Mayeux R Genetic variants in a CREB-dependent histone acetylation pathway influence memory performance in cognitively healthy elderly. Neurobiol Aging In Press, doi: 10.1016/j.neurobiolaging.2014.06.024 (2014). [DOI] [PMC free article] [PubMed]
- 14.Small SA et al. Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Ann Neurol 58, 909–919 (2005). [DOI] [PubMed] [Google Scholar]
- 15.Small SA & Petsko GA Endosomal recycling reconciles the Alzheimer’s disease paradox. Sci Transl Med 12, doi: 10.1126/scitranslmed.abb1717 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Small SA Isolating pathogenic mechanisms embedded within the hippocampal circuit through regional vulnerability. Neuron 84, 32–39, doi: 10.1016/j.neuron.2014.08.030 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gazzaley A, Sheridan MA, Cooney JW & D’Esposito M Age-related deficits in component processes of working memory. Neuropsychology 21, 532–539 (2007). [DOI] [PubMed] [Google Scholar]
- 18.Anguera JA et al. Video game training enhances cognitive control in older adults. Nature 501, 97–101, doi: 10.1038/nature12486 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.van Praag H et al. Plant-derived flavanol (−)epicatechin enhances angiogenesis and retention of spatial memory in mice. J Neurosci 27, 5869–5878, doi: 10.1523/JNEUROSCI.0914-07.2007 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Jones S Histone aceytlation in the aging hippocampus PhD thesis, Columbia University, (2010). [Google Scholar]
- 21.Ottaviani JI et al. Evaluation of (−)-epicatechin metabolites as recovery biomarker of dietary flavan-3-ol intake. Sci Rep 9, 13108, doi: 10.1038/s41598-019-49702-z (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Borges G, Ottaviani JI, van der Hooft JJJ, Schroeter H & Crozier A Absorption, metabolism, distribution and excretion of (−)-epicatechin: A review of recent findings. Mol Aspects Med 61, 18–30, doi: 10.1016/j.mam.2017.11.002 (2018). [DOI] [PubMed] [Google Scholar]
- 23.Horowitz AM et al. Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain. Science 369, 167–173, doi: 10.1126/science.aaw2622 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Bouchard J & Villeda SA Aging and brain rejuvenation as systemic events. J Neurochem 132, 5–19, doi: 10.1111/jnc.12969 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ozek C, Krolewski RC, Buchanan SM & Rubin LL Growth Differentiation Factor 11 treatment leads to neuronal and vascular improvements in the hippocampus of aged mice. Sci Rep 8, 17293, doi: 10.1038/s41598-018-35716-6 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Villeda SA et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90–94, doi: 10.1038/nature10357 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Palmer TD, Willhoite AR & Gage FH Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425, 479–494 (2000). [DOI] [PubMed] [Google Scholar]
- 28.Gage FH Neurogenesis in the adult brain. J Neurosci 22, 612–613 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Corral-Jara KF et al. Structurally related (−)-epicatechin metabolites and gut microbiota derived metabolites exert genomic modifications via VEGF signaling pathways in brain microvascular endothelial cells under lipotoxic conditions: Integrated multi-omic study. J Proteomics 263, 104603, doi: 10.1016/j.jprot.2022.104603 (2022). [DOI] [PubMed] [Google Scholar]
- 30.Huttemann M et al. (−)-Epicatechin is associated with increased angiogenic and mitochondrial signalling in the hindlimb of rats selectively bred for innate low running capacity. Clin Sci (Lond) 124, 663–674, doi: 10.1042/CS20120469 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Stringer TP, Guerrieri D, Vivar C & van Praag H Plant-derived flavanol (−)epicatechin mitigates anxiety in association with elevated hippocampal monoamine and BDNF levels, but does not influence pattern separation in mice. Transl Psychiatry 5, e493, doi: 10.1038/tp.2014.135 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Egan MF et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, 257–269, doi: 10.1016/s0092-8674(03)00035-7 (2003). [DOI] [PubMed] [Google Scholar]
- 33.Bana B & Cabreiro F The Microbiome and Aging. Annu Rev Genet 53, 239–261, doi: 10.1146/annurev-genet-112618-043650 (2019). [DOI] [PubMed] [Google Scholar]